While EGFR inhibition effectively enhanced the efficacy of Remodelin, and triple combination therapy (5-FU, Remodelin, and cetuximab) promoted tumor regression in our xenograft mouse models with wild-type KRAS/NRAS/BRAF CRC, the potential side effects of this combined treatment strategy must be considered. The gene discussed is KRAS; the disease is colorectal carcinoma.